The role of hormones, growth factors and vitamins in carcinogenesis

Critical Reviews in Oncology/Hematology

Volumn 23, Issue 2, 1996, Pages 95-130

  Lupulescu, Aurel ^a,b  

^a Medical Research Bldg ^*  (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANDROGEN; ANTIESTROGEN; ASCORBIC ACID; BETA CAROTENE; CALCITONIN; CORTICOSTEROID; ESTROGEN; GESTAGEN; GROWTH FACTOR; HORMONE; HYPOPHYSIS HORMONE; MELATONIN; PANCREAS HORMONE; PEPTIDE HORMONE; RETINOL; STEROID HORMONE; THYMUS HORMONE; THYROID HORMONE; VITAMIN; VITAMIN B GROUP; VITAMIN D; VITAMIN K GROUP;

CANCER; CANCER PREVENTION; CARCINOGENESIS; HUMAN; NONHUMAN; REVIEW;

EID: 0030175719     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/1040-8428(96)00198-9     Document Type: Review

References (355)

1. [1] White JW. The present position of the surgery of the hypertrophied prostate. Ann Surg 18:152-188, 1893.
2. [2] Ramazzini B. De Morbis Artificum, Diatriba (Diseases of workers). The Latin text of 1713, translated by WC Wright. New York: Hafner, 1964.
3. [3] Hunter J. Observations on Certain Parts of the Animal Oeconomy. London: Biblioteca Osteriana, 1786.
4. [4] Schinzinger AS. Über carcinoma mammae. Centralblatt Chirurgie (Beilage 51) 16:55-56, 1889.
5. [5] Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2:104-107;162-165, 1896.
6. [6] Lathrop AE, Loeb L. Further investigations on the origin of tumors in mice. III. On the part played by internal secretion in the spontaneous development of tumors. J Cancer Res 1:1-19, 1916.
7. [7] Engel D. Experimentelle Studien über die beeinflussung des tumor wachstums mit abbauprodukten (Abderhaldenschen optonen) von endokrinen drüsen bei maüsen. Z Krebsforsch 19:339-380, 1922.
8. [8] Lacassagne A. Apparition de cancers de la mammelle chez la souris mâle, soumise à des injections de folliculine. C R Acad Sci (Paris) 195:630-632, 1932.
9. [9] Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297, 1941.
10. [10] Huggins C, Moon RC, Morii S. Extinction of experimental mammary cancer. I. Estradiol-17β and progesterone. Proc Natl Acad Sci USA 48:379-386, 1962.
11. [11] Lupulescu A. Estrogen use and cancer risk. Review. Exp Clin Endocrinol 101:204-214, 1993.
12. [12] Lipschütz A. Steroid Hormones and Tumors. Baltimore: Williams and Wilkins, 1950.
13. [13] Gardner WU. Hormonal aspects of experimental tumorigenesis. Adv Cancer Res 1:173-232, 1953.
14. [14] Lupulescu A. Steroid Hormones. Bucharest Med. Publ. House, 1958.
15. [15] Furth J. Hormones as etiological agents in neoplasia. In: Becker F, ed. Cancer, volume 1. New York: Plenum Press, 1982; 89-134.
16. [16] Lupulescu A. Hormones and Carcinogenesis. New York: Praeger Scientific, 1983.
17. [17] Evaluation of Carcinogenic Risks to Humans: Oestrogens, progestins and combinations. IARC monographs (suppl. 7). Lyon (France): International Agency for Research on Cancer, 1987; 272-310.
18. [18] Yager JD, Zurlo J, Ni N. Sex hormones and tumor promotion in liver. Proc Soc Exp Biol Med 198:667-675, 1991.
19. [19] Lupulescu A. Hormonal regulation of epidermal tumor development. J Invest Dermatol 77:186-195, 1981.
20. [20] Holtzman S, Stone JP, Shellabarger CJ. Synergism of estrogens and x-rays in mammary carcinogenesis in female ACI rats. J Natl Cancer Inst 67:455-459, 1981.
21. [21] Telang NT, Suto A, Wong GY, Osborne MP, Bradlow HL. Induction by estrogen matabolite 16α-hydroxyestrone of genotoxic damage and aberrant proliferation in mouse mammary epithelial cells. J Natl Cancer Inst 84:634-638, 1992.
22. [22] Lupulescu A. Hormones and Vitamins in Cancer Treatment. Boca Raton, Boston: CRC Press, 1990.
23. 3H mice by diets containing diethylstilbestrol or 17β-estradiol. J Environ Pathol Toxicol 4:81-95, 1980.
24. [24] Sumi C, Longnecker DS, Roebuck BD, Brinck-Johnsen T. Inhibitory effects of estrogen and castration on the early stage of pancreatic carcinogenesis in Fischer rats treated with azaserine. Cancer Res 49:2332-2336, 1989.
25. [25] Li JJ, Li SA. Estrogen carcinogenesis in hamster tissues: A critical review. Endocr Rev 11:524-531, 1990.
26. [26] Lupulescu A. Hormonal regulation of neoplastic cell differentiation. J Cell Biol 97:66, 1983.
27. [27] Jordan VC. Long-term adjuvant tamoxifen therapy for breast cancer: The prelude to prevention. Cancer Treat Rev 17:15-36, 1990.
28. [28] Chander SK, Sahota SS, Evans TR, Luqmani YA. The biological evaluation of novel antioestrogens for the treatment of breast cancer. Crit Rev Oncol Hematol 15:243-269, 1993.
29. [29] Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in women. Science 259:633-638, 1993.
30. [30] Friedman MA, Trimble EL, Abrams JS. Tamoxifen: trials, tribulations, and trade-offs. J Natl Cancer Inst 86:478-479, 1994.
31. [31] Tannenbaum GS, Gurd W, Lapointe M, Pollak M. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology 130:3395-3401, 1992.
32. [32] Jordan VC, Lababidi MK, Langan-Fahey S. Suppression of mouse mammary tumorgenesis by long-term tamoxifen therapy. J Natl Cancer Inst 83:492-496, 1991.
33. [33] Osborne MP, Ruperto JF, Crowe JP, Rosen PP, Telang NT. Effect of tamoxifen on preneoplastic cell proliferation in N-nitroso-N-methylurea-induced mammary carcinogenesis. Cancer Res 52:1477-1480, 1992.
34. [34] Russo J, Calaf G, Russo IH. A critical approach to the malignant transformation of human breast epithelial cells with chemical carcinogens. Crit Rev Oncog 4:403-417, 1993.
35. [35] Zimniski SJ, Warren RC. Induction of tamoxifen-dependent rat mammary tumors. Cancer Res 53:2937-2939, 1993.
36. [36] Nayfield SG, Karp JE, Ford LG, Dorr FA, Kramer BS. Potential role of tamoxifen in prevention of breast cancer. J Natl Cancer Inst 83:1450-1459, 1991.
37. [37] Fornander T, Hellström A-C, Moberger B. Descriptive clinico-pathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85:1850-1855, 1993.
38. [38] Evans G, Bryant HU, Magee D, Sato M, Turner RT. The effects of raloxifene on tibia histomorphometry in ovariectomized rats. Endocrinology 134:2283-2288, 1994.
39. [39] Staffa JA, Newschaffer CJ, Jones JK, Miller V. Progestins and breast cancer. An epidemiologic review. Fertil Steril 57:473-491, 1992.
40. [40] Nordquist S. The synthesis of DNA and RNA in human carcinomatous endometrium in short-term incubation in vitro and its response to oestradiol and progesterone. J Endocrinol 48:29-38, 1970.
41. [41] Lupulescu A. Hormonal regulation of DNA synthesis in cancerous epidermal cells. J Cell Biol 87:103, 1980.
42. [42] Lupulescu A. Chemopreventive effect of progesterone on carcinoma formation in mice and rats. J Natl Cancer Inst 74:499-507, 1985.
43. [43] Lipschütz A, Iglesias R, Panasevich VI, Salinas S. Pathological changes induced in the uterus of mice with prolonged administration of progesterone and 19-nor-contraceptives. Br J Cancer 21:160-165, 1967.
44. [44] Huggins C. Endocrine-induced regression of cancers. Science 156:1050-1054, 1967.
45. [45] Dreicer R, Wilding G. Steroid hormone agonists and antagonists in the treatment of cancer. Cancer Invest 10:27-41, 1992.
46. [46] Noble R. The development of prostatic adenocarcinoma in NB rats following prolonged sex hormone administration. Cancer Res 37:1929-1933, 1977.
47. [47] Lacassagne A, Raynaud A. Sur le mécanisme d'une action préventive de la testostérone sur le carcinome mammaire de la souris. C R Soc Séances Soc Biol Fil (Paris) 131:586-588, 1939.
48. [48] Shimoji N, Imaida K, Hasegawa R et al. Enhancing effect of oxymetholone, an anabolic steroid, on development of liver cell foci in rats initiated with N-diethylnitrosamine. Cancer Lett 49:165-168, 1990.
49. [49] Sale GE, Lerner KG. Multiple tumors after androgen therapy. Arch Pathol Lab Med 101:600-603, 1977.
50. [50] Heilman FR, Kendall EC. The influence of 11-dehydro-17-hydroxycorticosterone (compound E) on the growth of a malignant tumor in the mouse. Endocrinology 34:416-420, 1944.
51. [51] Pearson OH, Eliel LP, Rawson, RW, Dobriner K, Rhoads CP. ACTH-and cortisone-induced regression of lymphoid tumors in man. Cancer 2:943-945, 1949.
52. [52] Mainwaring WI. Hormones and cancer. In: Franks LM, Teich NM, eds. Introduction to the Cellular and Molecular Biology of Cancer. Oxford: Oxford Med Publ, 1991; 357-385.
53. [53] Moon HD, Simpson ME, Li CH, Evans HM. Neoplasms in rats treated with pituitary growth hormone. I. Pulmonary and lymphatic tissues. Cancer Res 10:297-308, 1950.
54. [54] Moon HD, Simpson ME, Li CH, Evans HM. Neoplasms in rats treated with pituitary growth hormone. II. Adrenal glands. Cancer Res 10:364-370, 1950.
55. [55] Lupulescou A. Les phéochromocytomes expérimentaux. Ann Endocrinol (Paris) 22:459-468, 1961.
56. [56] Fradkin JE, Mills JL, Schonberger LB et al. Risk of leukemia after treatment with pituitary growth hormone. J Am Med Assoc 270:2829-2832, 1993.
57. [57] Gottschalk RG, Grollman A. Action of cortisone and ACTH on transplanted mouse tumors. Cancer Res 12:651-653, 1952.
58. [58] Weisburger JH. Hormones, chemicals and liver cancer. NZ Med J 67:44-56, 1968.
59. [59] Saez JM, Morera AM, Gallet D. Opposite effects of ACTH and glucocorticoids on adrenal DNA synthesis in vivo. Endocrinology 100:1268-1275, 1977.
60. [60] Meites J. Relation of prolactin and estrogen to mammary tumorigenesis in the rat. J Natl Cancer Inst 48:1217-1224, 1972.
61. [61] Russo IH, Russo J. From pathogenesis to hormone prevention of mammary carcinogenesis. Cancer Surv 5:649-670, 1986.
62. [62] Kharroubi A, Slaunwhite WR. The effect of prolactin on the Dunning R 3327 H rat prostatic adenocarcinoma. Endocr Res Commun 9:217-232, 1983.
63. [63] Mori T, Singtripop T, Kawashima S. Animal model of uterine adenomyosis: Is prolactin a potent inducer of adenomyosis in mice? Am J Obstet Gynecol 165:232-234, 1991.
64. [64] Lupulescu A. Enhancement of epidermal carcinoma formation by prolactin in mice. J Natl Cancer Inst 74:1335-1346, 1985.
65. 3H/HeJ female mice by suppression of prolactin. Cancer Res 33:2939-2946, 1973.
66. [66] Gandilhon P, Mélancon R, Djiane J, Kelly PA. N-Nitroso-N-methylurea-induced mammary tumors in the rat: Role of prolactin and a prolactin-lowering drug. J Natl Cancer Inst 70:105-109, 1983.
67. [67] Rudland PS, Hallowes RC, Durbin H, Lewis D. Mitogenic activity of pituitary hormones on cell cultures of normal and carcinogen-induced tumor epithelium from rat mammary glands. J Cell Biol 73:561-577, 1977.
68. [68] Forsberg J-G, Breistein LS. Prolactin and 3-methylcholanthrene induced cervical carcinoma. Effect of bromocriptine. Acta Pathol Microbiol Scand [A] 87:151-156, 1979.
69. [69] Lupulescu A, Petrovici A. Ultrastructure of the Thyroid Gland. Baltimore: Williams and Wilkins Co., 1968.
70. [70] Lupulescu A. Ultrastructural pathology of the thyroid gland. In: Motta PM, ed. Ultrastructure of Endocrine Cells and Tissues. Boston: M. Nijhoff Publ, 1984; 286-301.
71. [71] Williams ED. TSH and thyroid cancer. Horm Metab Res Suppl 23:72-75, 1990.
72. [72] Mittra I, Hayward JL. Hypothalamic-pituitary-thyroid axis in breast cancer. Lancet 1:885-888, 1974.
73. [73] Shellabarger CJ. Hypothyroidism and DMBA rat mammary carcinogenesis. Proc Am Assoc Cancer Res 10:79, 1969.
74. [74] Kirkland WL, Sorrentino GM, Sirbasku DA. Control of cell growth. III. Direct mitogenic effect of thyroid hormones on an estrogen-dependent rat pituitary tumor cell line. J Natl Cancer Inst 56:1159-1164, 1976.
75. [75] De Fesi CR, Surks MI. 3,5,3'-Triiodothyronine effects on the growth rates and cell cycle of cultured GC cells. Endocrinology 108:259-267, 1981.
76. [76] Harmon JT, Hilf R. Insulin and mammary cancer. In: Kellen JA, Hilf R, eds. Influences of Hormones in Tumor Development, volume II. Boca Raton: CRC Press, 1979; 111-128.
77. [77] Heuson JC, Legros N. Effect of insulin and of alloxan diabetes on growth of the rat mammary carcinoma in vivo. Eur J Cancer 6:349-351, 1970.
78. [78] Shafie SM, Grantham FH. Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J Natl Cancer Inst 67:51-56, 1981.
79. [79] Hilf R, Hissin PJ, Shafie SM. Regulatory interrelationships for insulin and estrogen action in mammary tumors. Cancer Res 38:4076-4085, 1978.
80. [80] Lupulescu A. Effect of prolonged insulin treatment on carcinoma formation in mice. Cancer Res 45:3288-3295, 1985.
81. [81] Shimizu N, Shimizu Y, Fuller BB. Cell-cycle analysis of insulin binding and internalization on mouse melanoma cells. J Cell Biol 88:241-244, 1981.
82. [82] Lupulescu A. Glucagon control of carcinogenesis. Endocrinology 113:527-534, 1983.
83. [83] Fatemi SH, Crouse DA, Sharp JG. Effects of gastrin and glucagon on DNA synthesis in gut epithelium. Anat Rec 196:54A, 1980.
84. [84] Wanless I, Medline A. Role of estrogens as promoters of hepatic neoplasia. Lab Invest 46:313-320, 1982.
85. [85] Yoshida H, Fukunishi R, Kato Y, Matsumoto K. Proges7 terone-stimulated growth of mammary carcinomas induced by 7,12-dimethylbenz[a]anthracene in neonatally androgenized rats. J Natl Cancer Inst 65:823-828, 1980.
86. [86] Pilot HC. Endogenous carcinogenesis: The role of tumor promotion. Proc Soc Exp Biol Med 198:661-666, 1991.
87. [87] Hall AK. Retinoic acid and serum modulation of thymosin β-10 gene expression in rat neuroblastoma cells. J Mol Neurosci 2:229-237, 1991.
88. [88] Dardenne M, Savino W, Gagnerault M-C, Itoh T, Bach J-F. Neuroendocrine control of thymic hormonal production. I. Prolactin stimulates in vivo and in vitro the production of thymulin by human and murine thymic epithelial cells. Endocrinology 125:3-12, 1989.
89. [89] Trainin N, Burstein Y, Ben-Efraim S, Goebel FD, Handze ZT. The use of THF, a thymic hormone for immunomodulation in cancer and AIDS. In: Lapis K, Eckhardt S, eds. Novel Approaches in Cancer Therapy. Budapest: Akad. Kiadó, 1987: 253-259.
90. [90] Lapin V. Influence of simultaneous pinealectomy and thymectomy on the growth and formation of metastases of the Yoshida sarcoma in rats. Exp Pathol 9:108-112, 1974.
91. [91] Danforth DN, Tamarkin L, Mulvihill JJ, Bagley CS, Lippman ME. Plasma melatonin and the hormone-dependency of human breast cancer. J Clin Oncol 3:941-948, 1985.
92. [92] Greig R, Dunnington D, Murthy U, Anzano M. Growth factors as novel therapeutic targets in neoplastic disease. Cancer Surv 7:653-674, 1988.
93. [93] Herlyn M, Kath R, Williams N, Valyi-Nagy I, Rodeck U. Growth-regulatory factors for normal, premalignant, and malignant human cells in vitro. Adv Cancer Res 54:213-232, 1990.
94. [94] Aaronson SA. Growth factors and cancer. Science 254:1146-1153, 1991.
95. [95] Cross M, Dexter TM. Growth factors in development, transformation, and tumorigenesis. Cell 64:271-280, 1991.
96. [96] Clarke R, Dickson RB, Lippman ME. Hormonal aspects of breast cancer: Growth factors, drugs and stromal interactions. Crit Rev Oncol Hematol 12:1-23, 1992.
97. [97] Pusztai L, Lewis CE, Lorenzen J, McGee J O'D. Growth factors: regulation of normal and neoplastic growth. J Pathol 169:191-201, 1993.
98. [98] Sporn MB, Roberts AB. Peptide growth factors are multifunctional. Nature 332:217-219, 1988.
99. [99] Canalis E. Clinical review 35: Growth factors and their potential clinical value. J Clin Endocrinol Metab 75:1-4, 1992.
100. [100] Garner A. Therapeutic potential of growth factors and their antagonists. Yale J Biol Med 65:715-723, 1992.
101. [101] Black RJ. Cytokines and oncogenes. J Exp Pathol 4:109-121, 1989.
102. [102] Gullick WJ. Growth factors and oncogenes in breast cancer. Prog Growth Factor Res 2:1-13, 1990.
103. [103] Damjanov I. Growth factor receptors. Curr Top Pathol 83:159-186, 1991.
104. [104] Myers C, Trepel J, Sartor O et al. Antigrowth factor strategies. Cancer 71:1172-1178, 1993.
105. [105] Anderson TL, Gorstein F, Osteen KG. Stromal-epithelial cell communication, growth factors, and tissue regulation. Lab Invest 62:519-521, 1990.
106. [106] Cohen S. The stimulation of epidermal proliferation by a specific protein (EGF). Dev Biol 12:394-407, 1965.
107. [107] Stoscheck CM, King LE. Role of epidermal growth factor in carcinogenesis. Cancer Res 46:1030-1037, 1986.
108. [108] Derynck R. Transforming growth factor α. Cell 54:593-595, 1988.
109. [109] Steel CM. Peptide regulatory factors and malignancy. Lancet 2:30-34, 1989.
110. [110] LeJeune S, Leek R, Horak E, Plowman G, Greenall M, Harris AL. Amphiregulin, epidermal growth factor receptor, and estrogen receptor expression in human primary breast cancer. Cancer Res 53:3597-3602, 1993.
111. [111] Shing Y, Christofori G, Hanahan D et al. Betacellulin: a mitogen from pancreatic β cell tumors. Science 259:1604-1607, 1993.
112. erbB2. Science 256:1205-1210, 1992.
113. [113] Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56:881-914, 1987.
114. [114] Prigent SA, Lemoine NR. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res 4:1-24, 1992.
115. [115] Ekstrand AJ, James CD, Cavenee WK, Seliger B, Pettersson RF, Collins VP. Genes for epidermal growth factor receptor, transforming growth factor α, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 51:2164-2172, 1991.
116. [116] Dickson RB, Johnson MD, El-Ashry D et al. Breast cancer: influence of endocrine hormones, growth factors and genetic alterations. Adv Exp Med Biol 330:119-141, 1993.
117. [117] Klijn JG, Berns EJ, Bontenbal M, Foekens J. Cell biological factors associated with the response of breast cancer to systemic treatment. Cancer Treat Rev 19(suppl. B):45-63, 1993.
118. [118] Frauman AG, Moses AC. Oncogenes and growth factors in thyroid carcinogenesis. Endocrinol Metab Clin North Am 19:479-490, 1990.
119. [119] Steiner MS. Role of peptide growth factors in the prostate. Review. Urology 42:99-110, 1993.
120. [120] Yoshida K, Tosaka A, Takeuchi S, Kobayashi N. Epidermal growth factor receptor content in human renal cell carcinoma. Cancer 73:1913-1918, 1994.
121. [121] Springer EA, Robinson JK. Patterns of epidermal growth factor receptors in basal and squamous cell carcinoma. J Dermatol Surg Oncol 17:20-24, 1991.
122. [122] Berthois Y, Dong XF, Martin PM. Regulation of epidermal growth factor-receptor by estrogen and antiestrogen in the human breast cancer cell line MCF-7. Biochem Biophys Res Commun 159:126-131, 1989
123. [123] Reynolds RK, Talavera F, Roberts JA, Hopkins MP, Menon KM. Regulation of epidermal growth factor and insulin-like growth factor I receptors by estradiol and progesterone in normal and neoplastic endometrial cell cultures. Gynecol Oncol 38:396-406, 1990.
124. [124] Traish AM, Wotiz HH. Prostatic epidermal growth factor receptors and their regulation by androgens. Endocrinology 121:1461-1467, 1987.
125. [125] Maddy SQ, Chisholm GD, Busuttil A, Habib FK. Epidermal growth factor receptors in human prostate cancer: correlation with histological differentiation of the tumour. Br J Cancer 60:41-44, 1989.
126. [126] Sporn MB, Roberts AB. Transforming growth factor β: recent progress and new challenges. J Cell Biol 119:1017-1021, 1992.
127. [127] Kimchi A, Wang X-F, Weinberg RA, Cheifetz S, Massagué J. Absence of TGF-β receptors and growth inhibitory responses in retinoblastoma cells. Science 240:196-199, 1988.
128. [128] Massagué J. Receptors for the TGF-β family. Cell 69:1067-1070, 1992.
129. [129] Kyprianou N, Isaacs JT. Identification of a cellular receptor for transforming growth factor-β in rat ventral prostate and its negative regulation by androgens. Endocrinology 123:2124-2131, 1988.
130. [130] Border WA, Ruoslahti E. Transforming growth factor-β in disease: the dark side of tissue repair. J Clin Invest 90:1-7, 1992.
131. [131] St.-Jacques S, Cymerman U, Pece N, Letarte M. Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-β binding protein of endothelial and stromal cells. Endocrinology 134:2645-2657, 1994.
132. [132] Arrick BA, Korc M, Derynck R. Differential regulation of expression of three transforming growth factor-β species in human breast cancer cell lines by estradiol. Cancer Res 50:299-303, 1990.
133. [133] Lahm H, Odartchenko N. Role of transforming growth factor β in colorectal cancer. Growth Factors 9:1-9, 1993.
134. 1. Cancer Res 47:6595-6599, 1987.
135. [135] Shirai Y, Kawata S, Tamura S et al. Plasma transforming growth factor-β in patients with hepatocellular carcinoma: comparison with chronic liver diseases. Cancer 73:2275-2279, 1994.
136. [136] Maciag T, Zhan X, Garfinkel S et al. Novel mechanisms of fibroblast growth factor 1 function. Recent Prog Horm Res 49:105-123, 1994.
137. [137] Baird A, Gonzalez AM, Buscaglia M, Lappi DA. Fibroblast growth factors: characterizations, biological activities and the development of receptor specific antagonists. In: Westermark B, Betsholtz C. Hökfelt B, eds. Growth Factors in Health and Disease. Amsterdam: Elsevier, 1990; 53-240.
138. [138] Zhou J, Serrero G. Fibroblast growth factor inhibits proliferation of a highly tumorigenic insulin-independent teratoma-derived cell line. Growth Factors 9:123-131, 1993.
139. [139] Gonzalez AM, Logan A, Ying W, Lappi DA, Berry M, Baird A. Fibroblast growth factor in the hypothalamic-pituitary axis: differential expression of fibroblast growth factor-2 and a high affinity receptor. Endocrinology 134:2289-2297, 1994.
140. [140] Folkman J. Peptides under study: bFGF. J Natl Cancer Inst 86:742-743, 1994.
141. [141] Ross R, Raines EW, Bowen-Pope DF. The biology of platelet derived growth factor. Cell 46:155-169, 1986.
142. [142] Rosenfeld RG, Lamson G, Pham H et al. Insulin like growth factor-binding proteins. Recent Prog Horm Res 46:99-159, 1990.
143. [143] Nielsen FC. The molecular and cellular biology of insulin-like growth factor II, Prog Growth Factor Res 4:257-290, 1992.
144. [144] Minuto F, Barreca A, Del Monte P, Cariola G, Torre GC, Giordano G. Immunoreactive insulin-like growth factor I (IGF-I) and IGF-I binding protein content in human thyroid tissue. J Clin Endocrinol Metab 68:621-626, 1989.
145. [145] Lee PD, Conover CA, Powell DR. Regulation and function of insulin-like growth factor-binding protein-1. Proc Soc Exp Biol Med 204:4-29, 1993.
146. [146] McGuire SE, Hilsenbeck SG, Figueroa JA, Jackson JG, Yee D. Detection of insulin-like growth factor binding protein (IGF-BPs) by ligand blotting in breast cancer tissues. Cancer Lett 77:25-32, 1994.
147. [147] Peyrat JP, Bonneterre J, Hecquet B et al. Plasma insulin-like growth factor-1 (IGF-1) concentrations in human breast cancer. Eur J Cancer 29[A]:492-497, 1993.
148. [148] Iwamura M, Sluss PM, Casamento JB, Cockett AT. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 22:243-252, 1993.
149. [149] Roy D, Narayan S. Alteration of insulin-like growth factor-1 (IGF-1) receptor binding sites in estrogen-induced kidney tumor. Proc Annu Meet Am Assoc Cancer Res 33:1618A, 1992.
150. [150] Nielsen FC, Ørskov C, Haselbacher G et al. Insulin-like growth factor II mRNA, peptides, and receptors in a thoracopulmonary malignant small round cell tumor. Cancer 73:1312-1319, 1994.
151. [151] Melino G, Stephanou A, Annicchiarico-Petruzzelli M, Knight RA, Finazzi-Agró A, Lightman SE. Modulation of IGF-2 expression during growth and differentiation of human neuroblastoma cells: retinoic acid may induce IGF-2. Neurosci Lett 151:187-191, 1993.
152. [152] Ravera F, Miglietta L, Pirani P, Ferrini S, Favoni RE. Suramin-induced growth inhibition and insulin-like growth factor-1 binding blockade in human breast carcinoma cell lines: potentially related events. Eur J Cancer 29[A]:225-230, 1993.
153. [153] Barde Y-A. The nerve growth factor family. Prog Growth Factor Res 2:237-248, 1990.
154. [154] Levi-Montalcini R. The nerve growth factor: thirty-five years later. EMBO J 6:1145-1154, 1987.
155. [155] Baker DL, Reddy UR, Pleasure D et al. Analysis of nerve growth factor receptor expression in human neuroblastoma and neuroepithelioma cell lines. Cancer Res 49:4142-4146, 1989.
156. [156] Eveleth DD. Nerve growth factor receptors: structure and function. In Vitro Cell Dev Biol 24:1148-1153, 1988.
157. [157] Rabizadeh S, Oh J, Zhong LT et al. Induction of apoptosis by the low-affinity NGF receptor. Science 261:345-348, 1993.
158. [158] Nakagawara A, Nakagawara AM, Scavarda NJ, Azar GC, Cantor AB, Brodeur GM. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N Engl J Med 328:847-854, 1993.
159. [159] Coley WB. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci 105:487-511, 1893.
160. [160] Balkwill FR. Tumor necrosis factor and cancer. Prog Growth Factor Res 4:121-137, 1992.
161. [161] Malik ST. Tumor necrosis factor: roles in cancer pathophysiology. Semin Cancer Biol 3:27-33, 1992.
162. [162] Behrends U, Hintermeier-Knabe R, Schultz-Hector S, Holler E, Bornkamm GW. Induction of tumor necrosis factor alpha (TNF-α) in normal mouse tissues by ionizing total body irradiation. Ann Hematol 67(supp. 2:A):165, 1993.
163. [163] Schütze S, Machleidt T, Krönke M. Mechanisms of tumor necrosis factor action. Semin Oncol 19(suppl, 4):16-24, 1992.
164. [164] Sidhu RS, Bolton AP. Tumor necrosis factor activities and cancer therapy; a perspective. Pharmacol Ther 57:79-128, 1993.
165. [165] Gherardi E, Sharpe M, Lane K. Properties and structure -function relationship of HGF-SF. Experientia 65:31-48, 1993.
166. [166] Jiang WG, Hallett MB, Puntis MC. Hepatocyte growth factor/scatter factor, liver regeneration and cancer metastasis. Br J Surg 80:1368-1373, 1993.
167. [167] Weidner KM, Hartmann G, Naldini L et al. Molecular characteristic of HGF-SF and its role in cell motility and invasion. Experientia 65:311-328, 1993.
168. [168] Comoglio PM. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells. Experientia 65:131-136, 1993.
169. [169] Weidner KM, Sachs M, Birchmeier W. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. J. Cell Biol 121:145-154, 1993.
170. [170] Bigazzi M, Brandi ML, Bani G, Sacchi TB. Relaxin influences the growth of MCF-7 breast cancer cells. Cancer 70:639-643, 1992.
171. [171] Vlasselaer PV. Leukemia inhibitory factor (LIF): a growth factor with pleiotropic effects on bone biology. Prog Growth Factor Res 4:337-353, 1992.
172. [172] Heath JK. Leukemia inhibitory factor. Ann Hematol 67(Suppl. 2:A):149, 1993.
173. [173] Shichiri M, Hirata Y, Nakajima T et al. Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J Clin Invest 87:1867-1871, 1991.
174. [174] Kennedy RL, Haynes WG, Webb DJ. Endothelins as regulators of growth and function in endocrine tissues. Clin Endocrinol 39:259-265, 1993.
175. [175] Männel DN, Rüschoff J, Orosz P. The role of TNF in tumor growth and metastasis. Res Immunol 144:364-369, 1993.
176. [176] Rubin JS, Bottaro DP, Aaronson SA. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim Biophys Acta 1155:357-371, 1993.
177. [177] Takano S, Gately S, Neville ME et al. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation and induction of urokinase-type plasminogen activator. Cancer Res 54:2654-2660, 1994.
178. [178] Fujimaki Y. Formation of gastric carcinoma in albino rats fed on deficient diets. J Cancer Res 10:469-477, 1926.
179. [179] Olson RE. Vitamins and carcinogenesis. J Nutr Sci Vitaminol (Tokyo). Spec. issue:313-316, 1992.
180. [180] Weisburger JH. Nutritional approach to cancer prevention with emphasis on vitamins, antioxidants, and carotenoids. Am J Clin Nutr 53(Suppl.1):226-237, 1991.
181. [181] Lupulescu A. The role of vitamins A, β-carotene, E and C in cancer cell biology. Review. Int J Vitam Nutr Res 64:3-14, 1994.
182. [182] Dorgan JF, Schatzkin A. Antioxidant micronutrients in cancer prevention. Hematol Oncol Clin North Am 5:43-68, 1991.
183. [183] Stähelin HB. Vitamins and cancer. Recent Results Cancer Res 108:227-234, 1988.
184. [184] Prasad KN, Edwards-Prasad J, Kumar S, Meyers A. Vitamins regulate gene expression and induce differentiation and growth inhibition in cancer cells. Arch Otolaryngol Head Neck Surg 119:1133-1140, 1993.
185. [185] Lippman SM, Kessler JF, Meyskens FL. Retinoids as preventive and therapeutic anticancer agents (Part II). Cancer Treat Rep 71:493-515, 1987.
186. [186] Lippman SM, Benner SE, Hong WK. Cancer chemoprevention. J Clin Oncol 12:851-873, 1994.
187. [187] Bertram JS, Kolonel LN, Meyskens FL. Rationale and strategies for chemoprevention of cancer in humans. Cancer Res 47:3012-3031, 1987.
188. [188] Moon RC, Mehta RG. Chemoprevention of experimental carcinogenesis in animals. Prev Med 18:576-591, 1989.
189. [189] Wolbach SB, Howe PR. Tissue changes following deprivation of fat-soluble A vitamin. J Exp Med 42:753-778, 1925.
190. [190] Kiemle-Kallee T, Porzsolt F. Retinoide in der onkologie. Dtsch med Wochenschr 118:390-394, 1993.
191. [191] Lotan R. Retinoids and squamous cell differentiation. In: Hond WK, Lotan R, eds. Retinoids in Oncology. New York: M. Dekker, 1993; 59-65.
192. [192] Breitman TR, Selonick SE, Collins SJ. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77:2936-2940, 1980.
193. [193] Lotan R. Effects of Vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochim Biophys Acta 605:33-91, 1980.
194. [194] Muto Y, Moriwaki H. Antitumor activity of vitamin A and its derivatives. J Natl Cancer Inst 73:1389-1393, 1984.
195. [195] Lupulescu A. Inhibition of DNA synthesis and neoplastic cell growth by vitamin A (retinol). J Natl Cancer Inst 77:149-156, 1986.
196. [196] Warrell RP, Frankel SR, Miller WH et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 324:1385-1393, 1991.
197. [197] Eliason JF, Kaufmann F, Tanaka T, Tsukaguchi T. Antiproliferative effects of the arotinoid Ro40-8757 on human cancer cell lines in vitro. Br J Cancer 67:1293-1298, 1993.
198. [198] Lupulescu A. Control of epithelial precancer cell transformation into cancer cells by vitamins. J Cell Biol 103:29, 1986.
199. [199] Bollag W. Prophylaxis of chemically induced benign and malignant epithelial tumors by vitamin A acid (retinoic acid). Eur J Cancer 8:689-693, 1972.
200. [200] Sherman MI. How do retinoids promote differentiation? In: Sherman MI, ed. Retinoids and Cell Differentiation. Boca Raton: CRC Press, 1986; 161-183.
201. [201] Bertram JS. Inhibition of neoplastic transformation in vitro by retinoids. Cancer Surv 2:243-262, 1983.
202. [202] Giese NA, Neary KE, Levine N, Lindell TJ, Duffy JJ. Inhibition by retinoic acid of murine retrovirus-induced cellular transformation and tumor formation. J Natl Cancer Inst 74:1135-1144, 1985.
203. [203] Hill DL, Grubbs CJ. Retinoids and cancer prevention. Annu Rev Nutr 12:161-181, 1992.
204. [204] Smith MA, Parkinson DR, Cheson BD, Friedman MA. Retinoids in cancer therapy. J Clin Oncol 10:839-864, 1992.
205. [205] Gerster H. Anticarcinogenic effect of common carotenoids. Int J Vitam Nutr Res 63:93-121, 1993.
206. [206] Bendich A, Olson JA. Biological actions of carotenoids. FASEB J 3:1927-1932, 1989.
207. [207] van Poppel G. Carotenoids and cancer: an update with emphasis on human intervention studies. Eur J Cancer 29[A]:1335-1344, 1993.
208. [208] Peto R, Doll R, Buckley JD, Sporn MB. Can dietary beta-carotene materially reduce human cancer rates? Nature 290:201-208, 1981.
209. [209] Stähelin HB. Beta-carotene and cancer. Br J Clin Pract 44:543-545, 1990.
210. [210] Stähelin HB, Gey KF, Eichholzer M, Lüdin E. Beta-carotene and cancer prevention: the Basel study. Am J Clin Nutr 53(Suppl.):265-269, 1991.
211. [211] Heinonen OP, Huttunen JK, Albanes D. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330:1029-1035, 1994.
212. [212] Mayne ST, Janerich DT, Greenwald P et al. Dietary beta carotene and lung cancer risk in U.S. nonsmokers. J Natl Cancer Inst 86:33-38, 1994.
213. [213] Singh VN, Gaby SK. Premalignant lesions: role of antioxidant vitamins and β-carotene in risk reduction and prevention of malignant transformation. Am J Clin Nutr 53(Suppl.):386-390, 1991.
214. [214] Grubbs CJ, Eto I, Juliana MM, Whitaker LM. Effect of canthaxanthin on chmically induced mammary carcinogenesis. Oncology 48:239-245, 1991.
215. [215] Tannenbaum A, Silverstone H. The genesis and growth of tumors. V. Effects of varying the level of B vitamins in the diet. Cancer Res 12:744-749, 1952.
216. [216] Kensler CJ, Sugiura K, Young NF, Halter CR, Rhoads CP. Partial protection of rats by riboflavin with casein against liver cancer caused by dimethylaminoazobenzene. Science 93:308-310, 1941.
217. [217] Rivlin RS. Riboflavin. Adv Exp Med Biol 206:349-355, 1986.
218. [218] Li J-Y, Taylor PR, Li B et al. Nutrition intervention trials in Linxian, China: multiple vitamin/mineral supplementation, cancer incidence, and disease-specific mortality among adults with esophageal dysplasia. J Natl Cancer Inst 85:1492-1498, 1993.
219. 6 deficiency and carcinogenesis. Adv Exp Med Biol 206:339-347, 1986.
220. 6 in BALB/c mice. J Natl Cancer Inst 78:951-959, 1987.
221. 6 and cancer: a novel pyridoxal 5-phosphate conjugate in tumor cells and blood of cancer patients. Anticancer Res 11:1281-1284, 1991.
222. 12 on p-dimethylaminoazobenzene-fed rats. Proc Soc Exp Biol Med 74:854-855, 1950.
223. 12 and folate deficiencies in carcinogenesis. Adv Exp Med Biol 206:313-330, 1986.
224. 12-deficiency in colon carcinogenesis. Proc Soc Exp Biol Med 163:350-353, 1980.
225. 12. J Am Med Assoc 259:1525-1530, 1988.
226. 12 on squamous metaplasia of the bronchial epithelium. Cancer 71:2477-2483, 1993.
227. [227] Rosenberg MR, Novicki DL, Jirtle RL, Novotny A, Michalopoulos G. Promoting effect of nicotinamide on the development of renal tubular cell tumors in rats initiated with diethylnitrosamine. Cancer Res 45:809-814, 1985.
228. [228] French FA. The influence of nutritional factors on pulmonary adenomas in mice. Adv Exp Med Biol 91:281-292, 1978.
229. [229] Bryan GT. The influence of niacin and nicotinamide on in vivo carcinogenesis. Adv Exp Med Biol 206:331-338, 1986.
230. [230] Jacobson EL. Niacin deficiency and cancer in women. J Am Coll Nutr 12:412-416, 1993.
231. [231] Leung PY, Miyashita K, Young M, Tsao CS. Cytotoxic effect of ascorbate and its derivatives on cultured malignant and nonmalignant cell lines. Anticancer Res 13:475-480, 1993.
232. 3H/10T1/2 cells. Cancer Res 40:2796-2801, 1980.
233. [233] Narra VR, Howell RW, Sastry KS, Rao DV. Vitamin C as a radioprotector against iodine-131 in vivo. J Nucl Med 34:637-640, 1993.
234. [234] Hanck AB. Vitamin C and cancer. Prog Clin Biol Res 259:307-320, 1988.
235. [235] Chen LH, Boissonneault GA, Glauert HP. Vitamin C, vitamin E and cancer. Anticancer Res 8:739-748, 1988.
236. [236] Mirvish SS. Experimental evidence for inhibition of N-nitroso compound formation as a factor in the negative correlation between vitamin C consumption and the incidence of certain cancers. Cancer Res 54(Suppl. 7):1948-1951, 1994.
237. [237] Lupulescu A. Ultrastructure and cell surface studies of cancer cells following vitamin C administration. Exp Toxicol Pathol 44:3-9, 1992.
238. [238] Schwartz J, Shklar G, Trickler D. Vitamin C enhances the development of carcinomas in the hamster buccal pouch experimental model. Oral Surg Oral Med Oral Pathol 76:718-722, 1993.
239. [239] Bartsch H, Pignatelli B, Calmels S, Ohshima H. Inhibition of nitrosation. Basic Life Sci 61:27-44, 1993.
240. [240] Cameron E, Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA 73:3685-3689, 1976.
241. [241] Moertel CG, Fleming TR, Creagan ET, Rubin J, O'Connell MJ, Ames MM. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy: a randomized double-blind comparison. N Engl J Med 312:137-141, 1985.
242. [242] Hunter DJ, Manson JE, Colditz GA et al. A prospective study of the intake of vitamins C, E, and A and the risk of breast cancer. N Engl J Med 329:234-240, 1993.
243. [243] Garland M, Willett WC, Manson JE, Hunter DJ. Antioxidant micronutrients and breast cancer. J Am Coll Nutr 12:400-411, 1993.
244. [244] Block G. Vitamin C status and cancer: epidemiologic evidence of reduced risk. Ann NY Acad Sci 669:280-290, 1992.
245. [245] Stähelin HB, Gey KF, Eichholzer M et al. Plasma antioxidant vitamins and subsequent cancer mortality in the 12-year-follow-up of the prospective Basel study. Am J Epidemiol 133:766-775, 1991.
246. [246] Lupulescu A. Vitamin C inhibits DNA, RNA and protein synthesis in epithelial neoplastic cells. Int J Vitam Nutr Res 61:125-129, 1991.
247. [247] Reichel H, Koeffler HP, Norman AW. The role of vitamin D endocrine system in health and disease. N Eng J Med 320:980-991, 1989.
248. [248] DeLuca HF. New concepts of vitamin D functions. Ann NY Acad Sci 669:59-68, 1992.
249. [249] DeLuca HF, Ostrem V. The relationship between the vitamin D system and cancer. Adv Exp Med Biol 206:413-429, 1986.
250. [250] Haussler MR, Mangelsdorf DJ, Komm BS et al. Molecular biology of the vitamin D hormone. Recent Prog Horm Res 44:263-305, 1988.
251. [251] Manolagas SC. Vitamin D and its relevance to cancer. Anticancer Res 7:625-638, 1987.
252. 3 receptors in human carcinomas: a pilot study. Cancer Res 51:2021-2024, 1991.
253. [253] Darwish H, DeLuca HF. Vitamin D-regulated gene expression. Crit Rev Eukaryot Gene Expr 3:89-116, 1993.
254. 3 receptors and actions in human prostate cancer cell lines. Endocrinology 132:1952-1960, 1993.
255. 3 receptors and induction of differentiation by the hormone. J Steroid Biochem 29:265-270, 1988.
256. 3 in the myeloid cell differentiation. Proc Soc Exp Biol Med 191:214-220, 1989.
257. [257] Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell proliferation. Lancet 1:188 191, 1989.
258. [258] Sergeev IN, Arkhapchev YP, Spirichev VB. Ascorbic acid effects on vitamin D hormone metabolism and binding in guinea pigs. J Nutr 120:1185-1190, 1990.
259. [259] Schräder M, Bendik I, Becker-André M. Carlberg C. Interaction between retinoic acid and vitamin D signaling pathways. J Biol Chem 268:17830-17836, 1993.
260. [260] Taimi M, Defacque H, Commes T et al. Effect of retinoic acid and vitamin D on the expression of interleukin-1 beta, tumor necrosis factor-α, and interleukm-6 in the human monocytic cell line U 937. Immunology 79:229-235, 1993.
261. [261] Hewison M. Vitamin D and the immune system. J Endocrinol 132:173-175, 1992.
262. 3 on proliferation and differentiation of CaCo-2 cells. Endocrinology 134:1710-1717, 1994.
263. [263] Beaty MM, Lee EY, Glauert HP. Influence of dietary calcium and vitamin D on colon epithelial cell proliferation and 1,2-dimethylhydrazine-induced colon carcinogenesis in rats fed high-fat diets. J Nutr 123:144-152, 1993.
264. [264] Colston KW, Mackay AG, James SY, Binderup L, Chander S. EB1089: a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 44:2273-2280, 1992.
265. [265] Newmark HL, Lipkin M. Calcium, Vitamin D, and colon cancer. Cancer Res 52(Suppl.):2067-2070, 1992.
266. [266] Kampman E, Giovannucci E, Van't Veer P et al. Calcium, vitamin D, dairy foods and the occurrence of colorectal adenomas among men and women in two prospective studies. Am J Epidemiol 139:16-29, 1994.
267. [267] Jaffe WG. The influence of wheat germ oil on the production of tumors in rats by methylcholanthrene. Exp Med Surg 4:278-282, 1946.
268. [268] Haber SL, Wissler, RW. Effect of vitamin E on carcinogenicity of methylcholanthrene. Proc Soc Exp Biol Med 111:774-775, 1962.
269. [269] Cook MG, McNamara P. Effect of dietary vitamin E on dimethylhydrazine-induced colonic tumors in mice. Cancer Res 40:1329-1331, 1980.
270. [270] Lupulescu A. Ultrastructural and cell surface studies of cancer epidermal cells following vitamin E administration. In: Bailey GW, ed. Proc Electr Microsc Soc Am (EMSA). San Francisco: San Francisco Press, 1986; 120-121.
271. [271] Trickler D, Shklar G. Prevention by vitamin E of experimental oral carcinogenesis. J Natl Cancer Inst 78:165-169, 1987.
272. [272] Odeleye OE, Eskelson CD, Mufti SI, Watson RR. Vitamin E inhibition of lipid peroxidation and ethanol-mediated promotion of esophageal tumorigenesis. Nutr Cancer 17:223-234, 1992.
273. [273] Knekt P. Vitamin E and cancer: epidemiology. Ann NY Acad Sci 669:269-276, 1992.
274. [274] Prasad KN, Edwards-Prasad J. Vitamin E and cancer prevention: recent advances and future potentials. J Am Coll Nutr 11:487-500, 1992.
275. [275] Chan AC. Partners in defense, vitamin E and vitamin C. Can J. Physiol Pharmacol 71:725-731, 1993.
276. [276] Garewal HS. Beta-carotene and vitamin E in oral cancer prevention. J Cell Biochem 17F(Suppl.):262-269, 1993.
277. [277] Blot WJ, Li J-Y, Taylor PR et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst 85:1483-1492, 1993.
278. [278] Steiner M. Influence of vitamin E on platelet function in humans. J Am Coll Nutr 10:466-473, 1991.
279. 3 inhibition of malignant murine cell growth and human tumor colony formation. Cancer Treat Rep 69:527-532, 1985.
280. 3 vitamin pre-treatment. Int J Cancer 40:575-579, 1987.
281. [281] Chlebowski RT, Akman SA, Block JB. Vitamin K in the treatment of cancer. Cancer Treat Rev 12:49-63, 1985.
282. [282] Golding J, Paterson M, Kinlen LJ. Factors associated with childhood cancer in a national cohort study. Br J Cancer 62:304-308, 1990.
283. [283] Golding J, Greenwood R, Birmingham K, Mott M. Childhood cancer, intramuscular vitamin K, and pethidine given during labour. Br Med J 305:341-346, 1992.
284. [284] Ekelund H, Finnström O, Gunnarskog J, Källén B, Larsson Y. Administration of vitamin K to newborn infants and childhood cancer. Br Med J 307:89-91, 1993.
285. [285] Klebanoff MA, Read JS, Mills JL, Shiono PH. The risk of childhood cancer after neonatal exposure to vitamin K. N Engl J Med 329:905-908, 1993.
286. [286] Draper G, McNinch A. Vitamin K for neonates: the controversy. Br Med J 308:867-868, 1994.
287. [287] Giovannucci E, Stampfer MJ, Colditz GA et al. Folate, methionine, and alcohol intake and risk of colorectal adenoma. J Natl Cancer Inst 85:875-884, 1993.
288. [288] Jensen EV, Jacobson HI. Basic guides to the mechanism of estrogen action. Recent Prog Horm Res 18:387-414, 1962.
289. [289] Jensen EV, DeSombre ER. Estrogen-receptor interaction. Science 182:126-134, 1973.
290. [290] Jiang SY, Jordan VC. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complimentary DNA for estrogen receptor. J Natl Cancer Inst 84:580-591, 1992.
291. [291] Van der Kwast TH, Schalken J, Ruizeveld de Winter JA et al. Androgen receptors in endocrine therapy-resistant human prostate cancer. Int J Cancer 48:189-193, 1991.
292. [292] de Voogt HJ, Rao BR, Geldof AA. How to define hormone-resistance. Prog Clin Biol Res 303:325-329, 1989.
293. [293] Roy AK. Regulation of steroid hormone action in target cells by specific hormone-inactivating enzymes. Proc Soc Exp Biol Med 199:265-272, 1992.
294. [294] Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 50:7415-7421, 1990.
295. [295] Swaneck GE, Fishman J. Covalent binding of the endogenous estrogen 16α-hydroxyestrone to estradiol receptor in human breast cancer cells: characterization and intranuclear localization. Proc Natl Acad Sci USA 85:7831-7835, 1988.
296. [296] Longcope C. Relationships of estrogen to breast cancer, of diet to breast cancer, and of diet to estradiol metabolism. J Natl Cancer Inst 82:896-897, 1990.
297. [297] Ross RK, Henderson BE. Do diet and androgens alter prostate cancer risk via a common etiologic pathway? J Natl Cancer Inst 86:252-254, 1994.
298. [298] Lupulescu A, Rogers J, Birmingham D. Hormonal control of preneoplastic epidermal cells during carcinogenesis in mice. J Cell Biol 79:187, 1978.
299. [299] Bursch W, Liehr JG, Sirbasku DA, Putz B, Taper H, Schulte-Hermann R. Control of cell death (apoptosis) by diethylstilbestrol in an estrogen-dependent kidney tumor. Carcinogenesis 12:855-860, 1991.
300. [300] Kerr JF, Winterford CM, Harmon BV. Apoptosis: its significance in cancer and cancer therapy. Cancer 73:2013-2026, 1994.
301. [301] Carson DA, Ribeiro JM. Apoptosis and disease. Lancet 341:1251-1254, 1993.
302. [302] Redpath NT, Proud CG. Molecular mechanisms in the control of translation by hormones and growth factors. Biochim Biophys Acta 1220:147-162, 1994.
303. 12 cell differentiation. Mol Cell Biol 12:1239-1247, 1992.
304. [304] Sorrentino V. Growth factors, growth inhibitors and cell cycle control. Review. Anticancer Res 9:1925-1936, 1989.
305. [305] Khazaie K, Schirrmacher V, Lichtner RB. EGF receptor in neoplasia and metastasis. Cancer Metastasis Rev 12:255-274, 1993.
306. [306] Volland S, Amtmann E, Sauer G. TNF accelerates the S-phase of the cell cycle in tumor cells. Int J Cancer 56:698-705, 1994.
307. [307] Moulton BC. Transforming growth factor-β stimulates endometrial stromal apoptosis in vitro. Endocrinology 134:1055-1060, 1994.
308. [308] Ross AC, Ternus ME. Vitamin A as a hormone: recent advances in understanding the actions of retinol, retinoic acid, and beta carotene. J Am Diet Assoc 93:1285-1290, 1993.
309. [309] McWhirter WR. Vitamin K and childhood cancer. Med J Aust 159:499, 1993.
310. [310] De Thé H, DeJean A. Retinoic acid receptors and oncogenesis. In: Brugge J, Curran T, Harlow E, McCormick F, eds. Origins of Human Cancer. Plainview: Cold Spring Harbor Lab Press. 1991; 377-382.
311. [311] Kent TA, Messina JL, Weinstock RS, Stein JP. Synergistic induction of gene 33 expression by retinoic acid and insulin. Endocrinology 134:2237-2244, 1994.
312. [312] Prabhala RH, Garewal HS, Hicks MJ, Sampliner RE, Watson RR. The effects of 13-cis-retinoic acid and beta-carotene on cellular immunity in humans. Cancer 67:1556-1560, 1991.
313. [313] Sies H, Stahl W, Sundquist AR. Antioxidant functions of vitamins: vitamins E and C, beta-carotene, and other carotenoids. Ann NY Acad Sci 669:7-20, 1992.
314. 6. In: Machlin LJ, ed. Handbook of Vitamins. New York: Marcel Dekker, 1991; 341-392.
315. [315] Gershoff SN. Vitamin C (ascorbic acid): new roles, new requirements? Nutr Rev 51:313-326, 1993.
316. [316] Chow CK. Vitamin E and oxidative stress. Free Radic Biol Med 11:215-232, 1991.
317. [317] Norman AW. Editorial: The vitamin D endocrine system: identification of another piece of the puzzle. Endocrinology 134:1601A-1601C, 1994.
318. 3. J Cell Biochem 49:26-31, 1992.
319. [319] Wiseman H. Vitamin D is a membrane antioxidant. FEBS Lett 326:285-288, 1993.
320. 3-induced cell cycle arrest and apoptotic cell death are accompanied by altered expression of c-fos and c-myc in nasopharyngeal carcinoma cells. Oncogene 8:2237-2244, 1993.
321. 3 (menadione) and related quinones, like tumor-promoting phorbol esters, alter the affinity of epidermal growth factor for its membrane receptors. J Biol Chem 255:8735-8739, 1980.
322. [322] Evans RM. The steroid and thyroid hormone receptor super-family. Science 240:889-893, 1988.
323. [323] Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as a major factor in human cancer. Cancer Res 42:3232-3239, 1982.
324. [324] Kovacs K. The pathology of Cushing's disease. J Steroid Biochem Mol Biol 45:179-182, 1993.
325. [325] Bernstein L, Ross RK. Endogenous hormones and breast cancer risk. Epidemiol Rev 15:48-65, 1993.
326. [326] Grady D, Rubin S, Petitti D et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 117:1016-1036, 1992.
327. [327] Jacobs HS, Loeffler FE. Postmenopausal hormone replacement therapy. Br Med J 305:1403-1408, 1992.
328. [328] Tulinius H, Egilsson V, Olafsdóttir GH, Sigvaldason H. Risk of prostate, ovarian, and endometrial cancer among relatives of women with breast cancer. Br Med J 305:855-857, 1992.
329. [329] Lowry S. Molecular basis for hormone-related cancer. Lancet 341:1630, 1993.
330. [330] Schuchard M, Landers JP, Sandhu NP, Spelsberg TC. Steroid hormone regulation of nuclear proto-oncogenes. Endocr Rev 14:659-669, 1993.
331. [331] Austoker J. Diet and cancer. Br Med J 308:1610-1614, 1994.
332. [332] Bennett WP, Hollstein MC, Metcalf RA et al. p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 52:6092-6097, 1992.
333. [333] Schwartz AG, Whitcomb JM, Nyce JW, Lewbart ML, Pashko LL. Dehydroepiandrosterone and structural analogs: a new class of cancer chemopreventive agents. Adv Cancer Res 51:391-424, 1988.
334. [334] Dyke GW, Craven JL, Hall R, Garner RC. Effect of vitamin C supplementation on gastric mucosal DNA damage. Carcinogenesis 15:291-295, 1994.
335. [335] Greenberg ER, Baron JA, Tosteson TD et al. A clinical trial of antioxidant vitamins to prevent colorectal adenoma. N Engl J Med 331:141-147, 1994.
336. [336] Weinberg RA. Oncogenes, antioncogenes, and the molecular bases of multistep carcinogenesis. Cancer Res 49:3713-3721, 1989.
337. [337] Egan SE, Giddings BW, Brooks MW, Buday L, Sizeland AM, Weinberg RA. Association of SOS Ras exchange protein with Grb2 is implicated in tyrosine kinase signal transduction and transformation. Nature 363:45-51, 1993.
338. [338] Cai J, Gill PS, Masood R et al. Oncostatin-M is an autocrine growth factor in Kaposi's sarcoma. Am J Pathol 145:74-79, 1994.
339. [339] Thoma B, Bird TA, Friend DJ, Gearing DP, Dower SK. Oncostatin M and leukemia inhibitory factor trigger overlapping and different signals through partially shared receptor complexes. J Biol Chem 269:6215-6222, 1994.
340. [340] Gould MN, Moore CJ, Zhang R. Wang B, Kennan WS, Haag JD. Limonene chemoprevention of mammary carcinoma induction following direct in situ transfer of v-Ha-ras. Cancer Res 54:3540-3543, 1994.
341. [341] McNamee D. Limonene trial in cancer. Lancet 342:801, 1993.
342. [342] Rehfeld JF, van Solinge WW. The tumor biology of gastrin and cholecystokinin. Adv Cancer Res 63:295-347, 1994.
343. [343] Rittmaster RS. Finasteride, N Engl J Med 330:120-125, 1994.
344. erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. J Natl Cancer Inst 86:1140-1145, 1994.
345. [345] Wouters W, van Dun J, Dillen A, Coene MC, Cools W, DeCoster R. Effects of liarozole, a new antitumoral compound, on retinoic acid-induced inhibition of cell growth and on retinoic acid metabolism in MCF-7 human breast cancer cells. Cancer Res 52:2841-2846, 1992.
346. [346] Glauber JG, Kiang DT. The changing role of hormonal therapy in advanced breast cancer. Semin Oncol 19:308-316, 1992.
347. [347] Abe J, Zhou W, Takuwa N et al. A fumagillin derivative angiogenesis inhibitor, AGM-1470, inhibits activation of cyclin-dependent kinases and phosphorylation of retinoblastoma gene product but not protein tyrosyl phosphorylation or protooncogene expression in vascular endothelial cells. Cancer Res 54:3407-3412, 1994.
348. [348] Lee MM, Donahoe PK. Mullerian inhibiting substance: A gonadal hormone with multiple functions. Endocr Rev 14:152-164, 1993.
349. [349] Cody V. Pseudovitamins. In: Machlin LJ, ed. Handbook of Vitamins, New York: Marcel Dekker, 1991: 575-582.
350. [350] Herbert V. The antioxidant supplement myth. Am J Clin Nutr 60:157-158, 1994.
351. [351] Block G, Patterson B, Subar A. Fruit, vegetables, and cancer prevention: a review of the epidemiological evidence. Nutr Cancer 18:1-29, 1992.
352. 3. Cancer Res 54:4057-4064, 1994.
353. [353] Ponta H, Sleeman J, Herrlich P. Tumor metastasis formation: cell-surface proteins confer metastasis-promoting or -suppressing properties. Biochim Biophys Acta 1198:1-10, 1994.
354. [354] Stone R. Environmental estrogens stir debate. Science 265:308-310, 1994.
355. [355] Higginson J. Environmental carcinogenesis. Cancer 72:971-977, 1993.